March 29, 2022 News by Lindsey Shapiro, PhD Trial Cleared for PIPE-307, Potential RRMS Myelin Restoration Therapy The U.S. Food and Drug Administration (FDA) has cleared a Phase 1b/2a trial of PIPE-307, Pipeline Therapeutics‘ investigational myelin-restoring treatment, in people with relapsing-remitting multiple sclerosis (RRMS). The trial will enroll about 45 RRMS patients from multiple U.S. sites who will be randomized to receive either three months…
March 21, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: SPMS Transition, NVG-291, PIPE-307, Foralumab MS Doctors, Nurses in UK Struggle With Marking Transition to SPMS The issue highlighted in this story isn’t just a problem in the U.K.; it’s a universal MS problem. People with MS often ask how they will know when their illness has transitioned from relapsing to progressive. I respond…
March 14, 2022 News by Margarida Maia, PhD PIPE-307, Aiming to Restore Myelin, Found Safe in Phase 1 Trial PIPE-307, an investigational myelin-restoring medication being developed by Pipeline Therapeutics for the treatment of multiple sclerosis (MS), appears to be safe and well tolerated in healthy adults. The results are from a Phase 1 clinical trial (NCT04725175) that evaluated the safety and tolerability of PIPE-307 in 70…
March 9, 2021 News by Forest Ray PhD Pipeline Testing PIPE-307 Remyelinating Compound in Healthy Volunteers Pipeline Therapeutics has initiated a Phase 1 clinical trial to investigate PIPE-307, its lead treatment candidate for multiple sclerosis (MS), in healthy volunteers. The trial (NCT04725175) will assess the compound’s safety, tolerability, and pharmacokinetics, or how the drug moves through the body. Up to 72 people, ages…
February 15, 2021 News by Forest Ray PhD Pipeline Raises $80M to Pursue Potential Myelin Restoring Therapy Pipeline TherapeuticsĀ announced that it has raised $80 million in investor financing to develop neuroregenerative therapies for neurological disorders, including those like multiple sclerosis (MS) that are marked by the loss of myelin. The money will support the research and development ofĀ several candidate therapies, with three aimed at promoting and…
April 6, 2018 News by Jose Marques Lopes, PhD New MS Therapy Company, Pipeline, to Focus on Rejuvenating Coating That Protects Nerve Cells A new company called Pipeline Therapeutics will focus on developing next-generation therapies for regenerating the key nerve-protection process that is damaged in multiple sclerosis. Roche, Inception Sciences,Ā and the venture capital firmĀ Versant VenturesĀ laid the groundwork for Pipeline byĀ establishing a partnershipĀ in June 2014 that formed the…